ClearPoint Neuro Reports Third Quarter 2024 Results
ClearPoint Neuro (CLPT) reported strong Q3 2024 results with record revenue of $8.1 million, representing 41% year-over-year growth. The company saw significant expansion in navigation and device revenue, reaching $2.9 million (53% increase), while overall product revenue more than doubled to $5.5 million. Notable achievements include activating five new global centers, reducing quarterly operational cash burn to $1.2 million, and fully repaying a $10 million convertible note. The company maintains its 2024 revenue guidance of $30.0-$33.0 million and reported cash and cash equivalents of $21.6 million as of September 30, 2024.
ClearPoint Neuro (CLPT) ha riportato risultati solidi per il terzo trimestre del 2024, con un fatturato record di 8,1 milioni di dollari, corrispondente a una crescita del 41% rispetto all'anno precedente. La società ha visto un notevole aumento nei ricavi da navigazione e dispositivi, che hanno raggiunto i 2,9 milioni di dollari (aumento del 53%), mentre il fatturato complessivo dei prodotti è più che raddoppiato a 5,5 milioni di dollari. Tra i risultati notevoli spiccano l'attivazione di cinque nuovi centri globali, la riduzione del fabbisogno di liquidità operativa trimestrale a 1,2 milioni di dollari e il completo rimborso di un prestito convertibile da 10 milioni di dollari. La società mantiene le stime di fatturato per il 2024 in un intervallo di 30,0-33,0 milioni di dollari e ha riportato disponibilità liquide e mezzi equivalenti pari a 21,6 milioni di dollari al 30 settembre 2024.
ClearPoint Neuro (CLPT) informó resultados sólidos para el tercer trimestre de 2024, con ingresos récord de 8,1 millones de dólares, lo que representa un crecimiento del 41% en comparación con el año anterior. La compañía experimentó una expansión significativa en los ingresos de navegación y dispositivos, alcanzando los 2,9 millones de dólares (aumento del 53%), mientras que los ingresos totales por productos más que se duplicaron a 5,5 millones de dólares. Entre los logros notables se incluyen la activación de cinco nuevos centros globales, la reducción de la quema de efectivo operativo trimestral a 1,2 millones de dólares y el reembolso total de un pagaré convertible de 10 millones de dólares. La compañía mantiene su guía de ingresos para 2024 en un rango de 30,0 a 33,0 millones de dólares y reportó 21,6 millones de dólares en efectivo y equivalentes al 30 de septiembre de 2024.
ClearPoint Neuro (CLPT)는 2024년 3분기 강력한 실적을 보고했으며, 8.1백만 달러의 기록적인 매출을 기록했습니다. 이는 지난해 같은 기간 대비 41% 성장한 것입니다. 회사는 내비게이션 및 장치 매출이 크게 증가하여 2.9백만 달러(53% 증가)에 도달했으며, 전반적인 제품 매출은 5.5백만 달러로 두 배 이상 증가했습니다. 주목할 만한 성과로는 다섯 개의 새로운 글로벌 센터를 활성화하고 분기 운영 현금 소모를 1.2백만 달러로 줄였으며, 1천만 달러의 전환사채를 전액 상환한 것입니다. 이 회사는 2024년 매출 가이드를 3천만 달러에서 3천3백만 달러로 유지하고 있으며, 2024년 9월 30일 현재 현금 및 현금성 자산은 2천1백6십만 달러를 보고했습니다.
ClearPoint Neuro (CLPT) a annoncé de solides résultats pour le troisième trimestre 2024, avec
ClearPoint Neuro (CLPT) hat im dritten Quartal 2024 starke Ergebnisse gemeldet, mit einem Rekordumsatz von 8,1 Millionen Dollar, was einem Wachstum von 41 % im Vergleich zum Vorjahr entspricht. Das Unternehmen verzeichnete eine signifikante Expansion im Umsatz mit Navigation und Geräten, der 2,9 Millionen Dollar erreichte (53 % Zuwachs), während der Gesamterlös aus Produkten auf mehr als 5,5 Millionen Dollar verdoppelt wurde. Zu den bemerkenswerten Erfolgen gehören die Aktivierung von fünf neuen globalen Zentren, die Reduzierung des quartalsweisen operativen Cash-Burns auf 1,2 Millionen Dollar sowie die vollständige Rückzahlung einer Wandelanleihe in Höhe von 10 Millionen Dollar. Das Unternehmen hält an seiner Umsatzprognose für 2024 von 30,0 bis 33,0 Millionen Dollar fest und berichtete zum 30. September 2024 über liquide Mittel und Zahlungsmitteläquivalente in Höhe von 21,6 Millionen Dollar.
- Record quarterly revenue of $8.1M, up 41% YoY
- Navigation and device revenue increased 53% to $2.9M
- Product revenue grew 127% to $5.5M
- Operational cash burn reduced 33% to $1.2M
- Eliminated all debt through early repayment of $10M convertible note
- Activated 19 new centers in 2024, triple the historic rate
- Gross margin improved to 60% from 57% YoY
- Operating expenses increased to $10.0M from $8.2M YoY
- Cash position decreased to $21.6M from $23.1M since December 2023
- Service and other revenue decreased by $0.7M in biologics segment
Insights
ClearPoint Neuro delivered an impressive Q3 2024 performance with multiple positive indicators. Revenue reached a record
- Product revenue more than doubled with
127% growth to$5.5 million - Navigation and device revenue increased
53% to$2.9 million - Operational cash burn reduced by
33% to$1.2 million - Debt-free status achieved after repaying
$10 million convertible note
The company maintains a healthy balance sheet with
Achieved Record Revenue and Growth of
SOLANA BEACH, CA / ACCESSWIRE / November 7, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its third quarter ended September 30, 2024.
Third Quarter Highlights
Reported quarterly revenue of
$8.1 million , a41% year-over-year increase;Accelerated growth of SmartFrame OR™ platform and ClearPoint Prism® Laser Therapy System, contributing to record navigation and device revenue of
$2.9 million , a53% year-over-year increase;Overall product revenue, including biologics and drug delivery, more than doubled year-over-year, growing
127% to$5.5 million ;Activated five new global centers in the third quarter for a total of 19 new centers so far this year; approximately three times our historic activation rate;
Continued patient enrollment in numerous cell and gene therapy trials for partners selected in FDA expedited review programs across multiple indications;
Full early repayment of the principal amount and interest on a
$10 million convertible note leaving the Company with no outstanding debt as of September 30, 2024;Quarterly operational cash burn reduced to
$1.2 million , a33% year-over-year decrease; andReported cash and cash equivalents totaling
$21.6 million as of September 30, 2024.
"The third quarter of 2024 was another example of continued execution of our four-pillar growth strategy, yielding another record revenue quarter,
Business Outlook
The Company reaffirms its full year 2024 revenue outlook of between
Financial Results - Quarter Ended September 30, 2024
Total revenue was
Biologics and Drug Delivery revenue, which includes sales of services and disposable products related to customer-sponsored preclinical and clinical trials utilizing our products, increased
Neurosurgery Navigation and Therapy revenue, which primarily consists of disposable product commercial sales related to cases utilizing the ClearPoint system, increased
Capital equipment and software revenue, consisting of sales of ClearPoint reusable hardware and software and related services, increased
Gross margin for the three months ended September 30, 2024, was
Operating expenses for the third quarter of 2024 were
At September 30, 2024, the Company had cash and cash equivalents totaling
Teleconference Information
Investors and analysts are invited to listen to a live broadcast review of the Company's 2024 third quarter on Thursday, November 7, 2024 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) which may be accessed online here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Yl0JL1Mt. Investors and analysts who would like to participate in the conference call via telephone may do so at (888) 428-7458, or at (862) 298-0702 if calling from outside the U.S. or Canada.
For those who cannot access the live broadcast, a replay will be available shortly after the completion of the call until December 7, 2024, by calling (877) 660-6853 or (201) 612-7415 if calling from outside the U.S. or Canada, and then entering conference I.D. number 413671. An online archive of the broadcast will be available on the Company's Investor website at https://ir.clearpointneuro.com/.
About ClearPoint Neuro
ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as preclinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
Forward-Looking Statements
Statements in this press release and in the teleconference referenced above concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company's products and services, the Company's expectation for revenues, operating expenses, the adequacy of cash and cash equivalent balances to support operations and meet future obligations, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. These forward-looking statements are based on management's current expectations and are subject to the risks inherent in the business, which may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: global and political instability, supply chain disruptions, labor shortages, and macroeconomic and inflationary conditions; future revenue from sales of the Company's products and services; the Company's ability to market, commercialize and achieve broader market acceptance for new products and services offered by the Company; the ability of our biologics and drug delivery partners to achieve commercial success, including their use of the Company's products and services in their delivery of therapies; the Company's ability to maintain its current relationships with biologics and drug delivery partners or enter into new relationships with such partners; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company's ability to obtain additional funding to support its research and development programs; the ability of the Company to manage the growth of its business; the Company's ability to attract and retain its key employees; and risks inherent in the research, development, and regulatory approval of new products. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2024, both of which have been filed with the Securities and Exchange Commission, and the Company's Quarterly Report on Form 10-Q for the three months ended September 30, 2024, which the Company intends to file with the Securities and Exchange Commission on or before November 14, 2024. The Company does not assume any obligation to update these forward-looking statements.
Contact:
Media Contact:
Jacqueline Keller, Vice President of Marketing
(888) 287-9109 ext. 4
info@clearpointneuro.com
Investor Relations:
Danilo D'Alessandro, Chief Financial Officer
(888) 287-9109 ext. 3
ir@clearpointneuro.com
CLEARPOINT NEURO, INC.
Consolidated Statements of Operations
(Unaudited)
(in thousands, except for share and per share data)
| For The Three Months Ended |
| |||||
| 2024 |
|
| 2023 |
| ||
Revenue: |
|
|
|
|
| ||
Product revenue | $ | 5,474 |
|
| $ | 2,410 |
|
Service and other revenue |
| 2,648 |
|
|
| 3,352 |
|
Total revenue |
| 8,122 |
|
|
| 5,762 |
|
Cost of revenue |
| 3,275 |
|
|
| 2,489 |
|
Gross profit |
| 4,847 |
|
|
| 3,273 |
|
Research and development costs |
| 3,315 |
|
|
| 2,429 |
|
Sales and marketing expenses |
| 3,549 |
|
|
| 2,841 |
|
General and administrative expenses |
| 3,155 |
|
|
| 2,900 |
|
Operating loss |
| (5,172 | ) |
|
| (4,897 | ) |
Other income (expense): |
|
|
|
|
|
|
|
Other expense, net |
| (11 | ) |
|
| (12 | ) |
Interest income, net |
| 209 |
|
|
| 100 |
|
Net loss | $ | (4,974 | ) |
| $ | (4,809 | ) |
Net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
Basic and diluted | $ | (0.18 | ) |
| $ | (0.20 | ) |
Weighted average shares used in computing net loss per share: |
|
|
|
|
|
|
|
Basic and diluted |
| 27,591,623 |
|
|
| 24,630,181 |
|
| For The Nine Months Ended |
| |||||
| 2024 |
|
| 2023 |
| ||
Revenue: |
|
|
|
|
| ||
Product revenue | $ | 14,053 |
|
| $ | 7,377 |
|
Service and other revenue |
| 9,566 |
|
|
| 9,768 |
|
Total revenue |
| 23,619 |
|
|
| 17,145 |
|
Cost of revenue |
| 9,259 |
|
|
| 7,544 |
|
Gross profit |
| 14,360 |
|
|
| 9,601 |
|
Research and development costs |
| 9,060 |
|
|
| 9,057 |
|
Sales and marketing expenses |
| 10,673 |
|
|
| 9,248 |
|
General and administrative expenses |
| 8,769 |
|
|
| 9,036 |
|
Operating loss |
| (14,142 | ) |
|
| (17,740 | ) |
Other income (expense): |
|
|
|
|
|
|
|
Other expense, net |
| (32 | ) |
|
| (25 | ) |
Interest income, net |
| 646 |
|
|
| 295 |
|
Net loss | $ | (13,528 | ) |
| $ | (17,470 | ) |
Net loss per share attributable to common stockholders: |
|
|
|
|
|
|
|
Basic and diluted | $ | (0.50 | ) |
| $ | (0.71 | ) |
Weighted average shares used in computing net loss per share: |
|
|
|
|
|
|
|
Basic and diluted |
| 26,840,119 |
|
|
| 24,599,191 |
|
CLEARPOINT NEURO, INC.
Consolidated Balance Sheets
(in thousands, except for share and per share data)
| September 30, |
|
| December 31, |
| ||
| (Unaudited) |
|
|
|
| ||
ASSETS |
|
|
|
|
| ||
Current assets: |
|
|
|
|
| ||
Cash and cash equivalents | $ | 21,573 |
|
| $ | 23,140 |
|
Accounts receivable, net |
| 3,875 |
|
|
| 3,211 |
|
Inventory, net |
| 7,059 |
|
|
| 7,911 |
|
Prepaid expenses and other current assets |
| 1,823 |
|
|
| 1,910 |
|
Total current assets |
| 34,330 |
|
|
| 36,172 |
|
Property and equipment, net |
| 1,695 |
|
|
| 1,389 |
|
Operating lease, right-of-use assets |
| 3,210 |
|
|
| 3,564 |
|
Software license inventory |
| 198 |
|
|
| 386 |
|
Licensing rights |
| 612 |
|
|
| 1,041 |
|
Other assets |
| 148 |
|
|
| 109 |
|
Total assets | $ | 40,193 |
|
| $ | 42,661 |
|
|
|
|
|
|
|
| |
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
Accounts payable | $ | 955 |
|
| $ | 393 |
|
Accrued compensation |
| 3,635 |
|
|
| 2,947 |
|
Other accrued liabilities |
| 1,176 |
|
|
| 1,053 |
|
Operating lease liabilities, current portion |
| 536 |
|
|
| 424 |
|
Deferred product and service revenue, current portion |
| 1,252 |
|
|
| 2,613 |
|
Total current liabilities |
| 7,554 |
|
|
| 7,430 |
|
Operating lease liabilities, net of current portion |
| 3,158 |
|
|
| 3,568 |
|
Deferred product and service revenue, net of current portion |
| 480 |
|
|
| 541 |
|
2020 senior secured convertible note payable, net |
| - |
|
|
| 9,949 |
|
Total liabilities |
| 11,192 |
|
|
| 21,488 |
|
Commitments and contingencies |
|
|
|
|
|
|
|
Stockholders' equity: |
|
|
|
|
|
|
|
Preferred stock, |
| - |
|
|
| - |
|
Common stock, |
| 276 |
|
|
| 247 |
|
Additional paid-in capital |
| 214,709 |
|
|
| 193,382 |
|
Accumulated deficit |
| (185,984 | ) |
|
| (172,456 | ) |
Total stockholders' equity |
| 29,001 |
|
|
| 21,173 |
|
Total liabilities and stockholders' equity | $ | 40,193 |
|
| $ | 42,661 |
|
CLEARPOINT NEURO, INC.
Consolidated Statements of Cash Flows
(Unaudited)
(in thousands)
| For The Nine Months Ended |
| |||||
| 2024 |
|
| 2023 |
| ||
Cash flows from operating activities: |
|
|
|
|
| ||
Net loss | $ | (13,528 | ) |
| $ | (17,470 | ) |
Adjustments to reconcile net loss to net cash flows from operating activities: |
|
|
|
|
|
|
|
Allowance for credit losses (recoveries) |
| (507 | ) |
|
| 903 |
|
Depreciation and amortization |
| 740 |
|
|
| 443 |
|
Share-based compensation |
| 5,204 |
|
|
| 4,536 |
|
Amortization of debt issuance costs and original issue discounts |
| 51 |
|
|
| 42 |
|
Amortization of lease right-of-use, net of accretion in lease liabilities |
| 692 |
|
|
| 590 |
|
Accretion of discounts on short-term investments |
| - |
|
|
| (126 | ) |
Increase (decrease) in cash resulting from changes in: |
|
|
|
|
|
|
|
Accounts receivable |
| (157 | ) |
|
| (662 | ) |
Inventory, net |
| 434 |
|
|
| 263 |
|
Prepaid expenses and other current assets |
| 88 |
|
|
| 241 |
|
Other assets |
| (40 | ) |
|
| 22 |
|
Accounts payable and accrued expenses |
| 1,373 |
|
|
| (1,023 | ) |
Lease liabilities |
| (635 | ) |
|
| (553 | ) |
Deferred revenue |
| (1,422 | ) |
|
| 243 |
|
Net cash flows from operating activities |
| (7,707 | ) |
|
| (12,551 | ) |
Cash flows from investing activities: |
|
|
|
|
|
|
|
Purchases of property and equipment |
| (12 | ) |
|
| (696 | ) |
Acquisition of licensing rights |
| - |
|
|
| (167 | ) |
Proceeds from maturities of short-term investments |
| - |
|
|
| 10,000 |
|
Net cash flows from investing activities |
| (12 | ) |
|
| 9,137 |
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
Proceeds from public offering of common stock, net of offering costs |
| 16,183 |
|
|
| - |
|
Repayment of 2020 senior secured convertible note |
| (10,000 | ) |
|
| - |
|
Proceeds from stock option exercises |
| 21 |
|
|
| - |
|
Payments for taxes related to net share settlement of equity awards |
| (340 | ) |
|
| (173 | ) |
Proceeds from issuance of common stock under employee stock purchase plan |
| 288 |
|
|
| 314 |
|
Net cash flows from financing activities |
| 6,152 |
|
|
| 141 |
|
Net change in cash and cash equivalents |
| (1,567 | ) |
|
| (3,273 | ) |
Cash and cash equivalents, beginning of period |
| 23,140 |
|
|
| 27,615 |
|
Cash and cash equivalents, end of period | $ | 21,573 |
|
| $ | 24,342 |
|
|
|
|
|
|
|
| |
SUPPLEMENTAL CASH FLOW INFORMATION |
|
|
|
|
|
|
|
Cash paid for: |
|
|
|
|
|
|
|
Income taxes | $ | - |
|
| $ | - |
|
Interest | $ | 480 |
|
| $ | 554 |
|
SOURCE: ClearPoint Neuro, Inc.
View the original press release on accesswire.com
FAQ
What was ClearPoint Neuro's (CLPT) revenue in Q3 2024?
How many new centers did CLPT activate in Q3 2024?
What is CLPT's revenue guidance for full-year 2024?